Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
03/2003
03/20/2003US20030055051 Having anti- inflammatory effect, which is less irritant, which has high safety and storage stability
03/20/2003US20030055046 Novel pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
03/20/2003US20030055024 Administering in divided doses an effective amount of a vascular damaging agent or a pharmaceutically acceptable salt thereof for production of a vascular damaging effect in a warm-blooded animal such as a human
03/20/2003US20030055006 Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use
03/20/2003US20030054974 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/20/2003US20030054446 Novel retina-specific human proteins C7orf9, C12orf7, MPP4 and F379
03/20/2003US20030054046 Hydrated dressing containing metal microbiocide
03/20/2003US20030053990 Virus vectors and methods of making and administering the same
03/20/2003CA2460092A1 A method of diagnosis and treatment and agents useful for same
03/20/2003CA2460075A1 Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases
03/20/2003CA2459890A1 Crystal structure of baff, and use thereof in drug design
03/20/2003CA2459882A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
03/20/2003CA2459527A1 Aryl substituted pyridinecarboxamides and their use as sodium channel blockers
03/20/2003CA2459515A1 Indole derivatives
03/19/2003EP1293570A2 Application of aprataxin gene to diagnosis and treatment for early-onset spinocerebellar ataxia (EAOH)
03/19/2003EP1293206A1 Water-based liquid preparation
03/19/2003EP1293126A1 Ophthalmic solution and contact lens solution
03/19/2003EP1292683A2 Secreted redox proteins
03/19/2003EP1292678A2 G-protein coupled receptors
03/19/2003EP1292620A2 Nuclear hormone receptor
03/19/2003EP1292619A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation
03/19/2003EP1292601A2 Naaladase inhibitors for treating retinal disorders and glaucoma
03/19/2003EP1292596A1 1,3,8-triaza-spiro[4,5]decan-4-one derivatives as neurokinin receptor antagonists
03/19/2003EP1292581A1 Bicyclic cyclohexylamines and their use as nmda receptor antagonists
03/19/2003EP1292577A2 Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker
03/19/2003EP1292576A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
03/19/2003EP1292572A1 Propanolaminotetralines, preparation thereof and compositions containing same
03/19/2003EP1292568A2 Benzamide ligands for the thyroid receptor
03/19/2003EP1292564A2 Aminoalcohol derivatives
03/19/2003EP1292279A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
03/19/2003EP1178984B1 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
03/19/2003EP1080069B1 Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
03/19/2003EP1051655A4 Methods and apparatus for accelerated orthokeratology
03/19/2003EP0964678B1 Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
03/19/2003EP0888309B1 Imidazole derivatives having affinity for alpha2 receptors activity
03/19/2003EP0831798B1 Use of selegiline to treat hearing loss in mammals
03/19/2003CN1404481A Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes
03/19/2003CN1404480A Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes
03/19/2003CN1404479A Novel 1,3-dihydro-2H-indol-2-one derivatives their preparing method and the pharmceutical composition containing the same
03/19/2003CN1404478A Pyridinylimidazoles
03/19/2003CN1404470A 2-OXo-1-pyrrolidine derivatives, process for preparing them and their uses
03/19/2003CN1404469A 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
03/19/2003CN1404468A Novel use of phenylheteroalkylamine derivatives
03/19/2003CN1403158A Eye drops containing chitosan derivative
03/19/2003CN1403096A Bear bile powder eye drop and its prepn
03/19/2003CN1403088A Medicine composition containing polydatin or its salt and its use in preparing medicine
03/19/2003CN1103217C Aqueous eye drops containing apafant as active ingredient
03/18/2003US6535943 Information processing device enabling floating interrupt to be pending and a method executing an interrupt condition change instruction
03/18/2003US6534655 Indeno[1,2-C]pyrazole derivatives for inhibiting tyrosine kinase activity
03/18/2003US6534544 Methods of treatment with compounds having RARα receptor specific or selective activity
03/18/2003US6534541 Treatment of ocular disorders
03/18/2003US6534518 Polysubstituted 6-phenylphenanthridines with PDE-IV inhibiting activity
03/18/2003US6534261 Regulation of endogenous gene expression in cells using zinc finger proteins
03/18/2003US6534082 Method of treating disorders of the eye
03/18/2003US6534059 Administering to the eye of said mammal a composition comprising antibody to interferon gamma.
03/18/2003US6533769 Method for use in cataract surgery
03/18/2003CA2216417C Controlled release of miotic and mydriatic drugs in the anterior chamber
03/18/2003CA1341425C Antibodies to angiogenin: immunotherapeutic agents
03/13/2003WO2003020771A1 Chitosan-thio-amidine conjugates and their cosmetic as well as pharmaceutic use
03/13/2003WO2003020759A2 A caspase- 8 binding protein, its preparation and use
03/13/2003WO2003020724A1 Polycyclic guanine phosphodiesterase v inhibitors
03/13/2003WO2003020700A2 SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF
03/13/2003WO2003020324A2 Methods for sterilizing preparations of digestive enzymes
03/13/2003WO2003020284A1 Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma
03/13/2003WO2003020283A2 Method for treating diabetic retinopathy
03/13/2003WO2003020281A1 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma
03/13/2003WO2003020275A1 Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders
03/13/2003WO2003020257A2 USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
03/13/2003WO2003020219A2 Aerosolized decongestants for the treatment of sinusitis
03/13/2003WO2003020172A1 An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues
03/13/2003WO2003020026A1 Methods for treating disorders using plant extracts
03/13/2003WO2002096317A3 Method for treating glaucoma vi
03/13/2003WO2002089743A3 Use of compositions for treating rosacea
03/13/2003WO2002076950A3 Imidiazole derivatives and their use as agonists selective at alpha 2b or 2b/2c adrenergic receptors
03/13/2003WO2002063012A3 Ragweed allergens
03/13/2003WO2002053519A3 Hydrophobic polyamine analogs and methods for their use
03/13/2003WO2002046191A3 Urea substituted imidazoquinoline ethers
03/13/2003WO2002046188A3 Amido ether substituted imidazoquinolines
03/13/2003WO2002043763A3 Combination of gaba agonists and aldose reductase inhibitors
03/13/2003WO2002043762A3 Combination of gaba agonists and sorbitol dehydrogenase inhibitors
03/13/2003WO2002042332A3 Truncated cd200
03/13/2003WO2002042319A3 2-substituted estrogens as antiangiogenic agents
03/13/2003WO2002032411A3 Combination of statins and sorbitol dehydrogenase inhibitors
03/13/2003WO2002011708A3 Methods for inducing apolipoprotein e secretion
03/13/2003WO2002000690A3 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
03/13/2003US20030050461 Protein for use in the diagnosis, prevention and treatment of metabolic, developmental, nutrient transport and cell proliferation disorders
03/13/2003US20030050460 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cardiovascular and bone disorders
03/13/2003US20030050337 Polymorphic B Form of 3-(cyclopropylmethoxy)-4-[4(methylsulfonyl)phenyl]-5,5- dimethyl-5H-furan-2-one
03/13/2003US20030050314 Treating bone disorder caused by osteoclasts, tumor growth and tumor metastasis, prophylaxis of cardiovascular disorders, nephropathies or retinopathies
03/13/2003US20030050310 Hydroxamic acid derivatives as proteinase inhibitors
03/13/2003US20030050303 Treating neutrophils and eosinophils in the tissue of the eye or nasal mucous membrane
03/13/2003US20030050301 A drug mixture additionally comprising an antihypertensive agent or it's prodrug and a carrier, vehicle or diluent
03/13/2003US20030050299 An intermediates for enantiomeric synthesis cermamide-like inhibitors; producing antilipemic agents
03/13/2003US20030050298 A sulfonamide substituted diphenyl thiourea compounds treating a chemokine mediated disease
03/13/2003US20030050283 Composition for the treatment and/or prevention of macular degeneration, method for its manufacture, and its use for treating the eye
03/13/2003US20030050278 Agent and food for inhibiting IgE antibody
03/13/2003US20030050272 Purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase nucleic acids and polypeptides
03/13/2003US20030050265 A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding transforming growth factor-beta 2
03/13/2003US20030050255 An ophthalmic formulation containing an ascomycin and at least one polymer selected from ethylene oxide-propylene oxide copolymer and a crosslinked acrylic acid polymer
03/13/2003US20030050247 Peptides which are modified with at least one hydrocarbyl group and which possess antimicrobial acitivity
1 ... 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 ... 531